| Aspire Home Care | |
| 2040 Ne Coachman Rd Ste C, Clearwater, Florida 33765 | |
| (727) 799-5300 | |
| Name | Aspire Home Care |
|---|---|
| Location | 2040 Ne Coachman Rd Ste C, Clearwater, Florida |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 683187 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 33702, 33704, 33705, 33706, 33707, 33708, 33709, 33710, 33711, 33712, 33713, 33714, 33715, 33716, 33741, 33755, 33756, 33759, 33760, 33761, 33763, 33764, 33765, 33767, 33770, 33771, 33772, 33773, 33774, 33776, 33777, 33778, 33781, 33782, 33785, 34655, 34667, 34677, 34683, 34684, 34685, 34688, 34689, 34690, 34691, 34695, 34698 |
| NPI Number | 1144621806 |
| Organization Name | ALMENDRAL PARTNERS LLC |
| Doing Business As | ASPIRE HOME CARE |
| Address | 2040 Ne Coachman Rd Ste C, Clearwater, FL 33765 |
| Phone Number | 727-799-5300 |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
| Quality Rating: |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 93.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.8 | 99.6 |
| How often the home health team checked patients for depression | 96.7 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 83.2 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 65.8 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 63.3 | 96.4 |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 84.8 | 79.6 |
| How often patients got better at getting in and out of bed | 90 | 81.1 |
| How often patients got better at bathing | 99.4 | 82.3 |
| How often patients’ breathing improved | 89.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 96.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 100 | 75 |
| How often home health patients had to be admitted to the hospital | 17.3 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 12.5 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 74.4 | 94 |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
The patient survey data of Aspire Home Care is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 89 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 86 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 90 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 86 | 78 |
News Archive
Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
January is National Glaucoma Awareness Month, an important time to spread the word about this sight-stealing disease.
The N.J. effort must secure federal approval first. Also in Medicaid news, a judge in California this week will hear arguments in the challenge to the state's plans for adult health care.
How many heart transplant programs do we really need? That was a question posed by a group of investigators, including Vanderbilt University Medical Center's Ashish Shah, M.D., in a novel study that used a computerized algorithm to highlight the value of high-volume transplant centers with corresponding improved outcomes.
› Verified 6 days ago
Angels Care Home Health Location: 1700 N Mcmullen Booth Rd Ste B3, Clearwater, Florida 33759 Ratings: Phone: (727) 791-7951 | |
Trilogy Home Healthcare Location: 25400 Us 19 North Ste 164, Clearwater, Florida 33763 Ratings: Phone: (727) 803-6982 | |
Kindred At Home Location: 380 Park Place Blvd Ste 100, Clearwater, Florida 33759 Ratings: Phone: (727) 531-0300 | |
Empath Home Health Location: 5771 Roosevelt Blvd Bldg 610, Clearwater, Florida 33760 Ratings: Phone: (727) 586-4432 | |
Interim Healthcare Gulf Coast Inc Location: 1940 Drew St Ste A, Clearwater, Florida 33765 Ratings: Phone: (727) 441-9585 | |
Mederi Caretenders Location: 50 South Belcher Road Ste 112, Clearwater, Florida 33765 Ratings: Phone: (727) 584-1824 |